The treatment involves mesenchymal stromal cells, which are specialized cells that can help regulate the immune system, that have been grown in a laboratory setting. These cells are administered through an intravenous infusion, a method where the medicine is delivered directly into a vein. During the course of the study, participants will receive these cells to see how well they can manage the symptoms and progression of the disease when other standard treatments have failed.

The study uses an investigational product called MaaT013, which is a preparation of allogeneic faecal microbiota, pooled given as a rectal solution. This means that healthy bacteria taken from several donors are mixed together and introduced into the lower intestine to help restore a normal balance of gut microbes. In addition, participants may receive the antibiotic vancomycin taken by mouth to control any unwanted bacteria while the new microbes settle in.

The purpose of the research is to find out whether MaaT013 can be given safely and is tolerated by pediatric and adolescent participants, and whether it can be administered feasibly in this age group. Participants receive the study medication at scheduled visits and are monitored for side effects, ability to keep the solution in the rectum for the required time, and changes in stress or anxiety. Follow‑up visits continue for up to twelve months, during which physicians check for improvement in gastrointestinal symptoms, the need for additional medicines, and overall health status.

The treatment being tested consists of allogeneic adipose tissue derived mesenchymal stromal cells. These are special cells taken from fat tissue of a donor that have been modified in a laboratory to produce two specific proteins, CXCR4 and IL-10, which help manage immune responses. These modified cells are provided as a cell suspension for injection and are delivered through an intravenous infusion, which means the medicine is put directly into a vein.

During the study, participants will receive these cell infusions. Following the administration of the treatment, the medical team will monitor the participants closely over a period of time to observe any side effects or reactions to ensure the process is safe.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The study tests whether adding itolizumab to corticosteroid treatment works better than adding placebo to corticosteroids for patients with Acute Graft Versus Host Disease. The medication is given through an intravenous infusion (delivered directly into a vein) over a period of 84 days. The total amount of medication given depends on the patient’s weight.

During the study, participants receive either itolizumab (given as EQ001 solution for infusion) or a matching placebo along with corticosteroid treatment. The study uses specific methods to ensure neither the doctors nor the patients know which treatment each person receives. The main goal is to see how well patients respond to the treatment, particularly in the early stages of the disease.

The study will use several medications including cyclophosphamide, mycophenolate mofetil, and tacrolimus. One group of patients will receive Grafalon, which contains antibodies that affect the immune system, while another group will receive a different combination of medications. These medications will be given through infusion into a vein or taken by mouth.

The treatment will be given around the time of the stem cell transplantation. Patients will receive their assigned medications according to a specific schedule, with some treatments lasting a few days and others continuing for several months. The medications are used to help the body accept the transplanted cells and prevent rejection.

The purpose of the study is to assess the safety and effectiveness of these cell therapies in treating severe acute GvHD. Participants in the study will receive the treatment through an infusion, which means the solution is administered directly into the bloodstream. The study will monitor how well patients respond to the treatment over a period of time, specifically looking at their response at 28 days and 56 days after starting the treatment. The study will also track any side effects or complications that may arise during the treatment period.

Throughout the study, researchers will evaluate the overall survival of patients, which refers to the time from the start of the treatment until death from any cause. They will also look at the occurrence of infections or other complications related to the transplant. The study aims to provide valuable information on whether these new cell therapies can offer a safe and effective treatment option for patients with severe acute GvHD who do not respond to standard steroid treatments.

Participants in the study will receive one of the two conditioning regimens, followed by the stem cell transplant. The medications will be administered through an intravenous route, meaning they will be given directly into a vein. The study will monitor the patients for several outcomes, including the incidence of severe GVHD that does not respond to standard treatments, as well as other factors like overall survival, disease-free survival, and the occurrence of infections. The trial will also assess how well the donor’s cells are accepted by the patient’s body and how the immune system recovers over time.

This study is designed to help improve the understanding of how different conditioning regimens affect the success of stem cell transplants and the health of patients with blood cancers. By comparing the two regimens, researchers hope to find the most effective way to reduce the risk of complications like GVHD and improve the overall outcomes for patients undergoing this type of treatment. The trial is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to assess the safety and effectiveness of AAT in preventing GVHD. Participants in the study will receive either the AAT treatment or a placebo. The study will follow participants over a period of time to monitor for any signs of GVHD, as well as any side effects or other health changes. The study aims to determine if AAT can reduce the occurrence of GVHD and improve the overall health outcomes for patients receiving HCT.

Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study will provide valuable information on whether AAT can be a beneficial treatment option for preventing GVHD in patients undergoing HCT. This research is important for improving the care and outcomes for patients who require this type of transplant.

Participants in this study will continue to receive ibrutinib, which is taken in the form of a capsule. The study will monitor the participants’ health and any changes in their condition while they are on the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study aims to ensure that ibrutinib remains safe and effective for those who have been using it and to understand its long-term impact on their health.

The study will take place over several years, allowing researchers to collect comprehensive data on the long-term use of ibrutinib. Participants will be regularly assessed to track any side effects or changes in their disease status. This information will help in understanding how ibrutinib can be used most effectively in treating these conditions and ensuring the well-being of those who rely on it for their treatment.